A number of firms have modified their ratings and price targets on shares of FocalTherics (NASDAQ: FOCL) recently:
- 8/25/2026 – FocalTherics had its “buy” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
- 8/17/2026 – FocalTherics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 8/15/2026 – FocalTherics was downgraded by Wall Street Zen from “hold” to “sell”.
- 8/14/2026 – FocalTherics had its “neutral” rating reaffirmed by Piper Sandler. They now have a $4.00 price target on the stock.
- 8/1/2026 – FocalTherics was upgraded by Wall Street Zen to “hold”.
- 7/17/2026 – FocalTherics was given a new $15.00 price target by Mizuho. They now have an “outperform” rating on the stock.
- 7/17/2026 – FocalTherics was upgraded by Mizuho to “strong-buy”.
Insider Activity
In other FocalTherics news, Director Fran Schulz purchased 10,000 shares of the stock in a transaction on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director owned 15,100 shares of the company’s stock, valued at $71,725. This trade represents a 196.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Ryan Rhodes acquired 21,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $99,750.00. Following the completion of the acquisition, the chief executive officer owned 626,649 shares of the company’s stock, valued at $2,976,582.75. This trade represents a 3.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 116,000 shares of company stock worth $551,000. 10.10% of the stock is currently owned by corporate insiders.
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Featured Stories
- Five stocks we like better than FocalTherics
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
- Analysts See Major Upside for This Top-10 Performing S&P 500 Stock
- Cook Out, Silicon In: Will Ternus Trigger Apple’s Edge AI Boom?
Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.
